Arcus Biosciences, Inc.
RCUSNext catalyst
Zimberelimab
Non Small Cell Lung Cancer
Get an email about RCUS's next catalysts
Track Arcus Biosciences (RCUS) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 8 more upcoming events in our data (earnings, Phase 2 readout, trial start).See the timeline
9 upcoming, 1 past
Zimberelimab Phase 2 Est. Readout
Estimated primary completion for Zimberelimab trial (NCT04791839) in Non Small Cell Lung Cancer. Topline data typically follows completion by weeks to months.
SourceRCUS Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.92 | FQ end Sep/2026 | Call: amc
Quemliclustat Phase 2 Est. Readout (SBRT-AMICO)
Estimated primary completion for Quemliclustat trial (NCT05688215) in Borderline Resectable Pancreatic Adenocarcinoma. Topline data typically follows completion by weeks to months.
SourceZimberelimab Phase 2 Est. Readout
Estimated primary completion for Zimberelimab trial (NCT06048133) in Biliary Tract Carcinoma. Topline data typically follows completion by weeks to months.
SourceEtrumadenant (AB928) Phase 2 Est. Readout (PANTHER)
Estimated primary completion for Etrumadenant (AB928) trial (NCT05024097) in Rectal Cancer. Topline data typically follows completion by weeks to months.
SourceTrial Start - PEAK-1
Arcus Biosciences announced full enrollment of the PEAK-1 trial by year-end 2026 and disclosed cash runway extending into the second half of 2028.
Zimberelimab Phase 2 Est. Readout (VELOCITY-HNSCC)
Estimated primary completion for Zimberelimab trial (NCT06727565) in Head and Neck Squamous Cell Carcinoma. Topline data typically follows completion by weeks to months.
SourceQuemliclustat Phase 2 Est. Readout (AIRPanc)
Estimated primary completion for Quemliclustat trial (NCT06048484) in Pancreatic Ductal Adenocarcinoma. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
Casdatifan
Metastatic Clear Cell Renal Cell Carcinoma
Quemliclustat
Gastrointestinal Tract Malignancies
Zimberelimab
Non Small Cell Lung Cancer
Domvanalimab
Advanced Upper Gastrointestinal Tract Adenocarcinoma
Modified FOLFIRINOX
Pancreatic Ductal Adenocarcinoma
m-FOLFOX-6 regimen
Metastatic Colorectal Cancer
Domvanalimab (DOM)
Lung Cancer
Zimberelimab (AB122)
Rectal Cancer
Etrumadenant (ETRUMA)
Lung Cancer
Platinum-Based Doublet
Advanced Non-Small Cell Lung Cancer
AB680
Metastatic Colorectal Cancer
Etrumadenant
Prostatic Neoplasms, Castration-Resistant
Etrumadenant (AB928)
Rectal Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Casdatifan | Phase 3 | Metastatic Clear Cell Renal Cell Carcinoma | - | - |
Quemliclustat | Phase 3 | Gastrointestinal Tract Malignancies | - | - |
Zimberelimab | Phase 3 | Non Small Cell Lung Cancer | - | - |
Domvanalimab | Phase 3 | Advanced Upper Gastrointestinal Tract Adenocarcinoma | - | - |
Modified FOLFIRINOX | Phase 2 | Pancreatic Ductal Adenocarcinoma | - | - |
m-FOLFOX-6 regimen | Phase 2 | Metastatic Colorectal Cancer | - | - |
Domvanalimab (DOM) | Phase 2 | Lung Cancer | - | - |
Zimberelimab (AB122) | Phase 2 | Rectal Cancer | - | - |
Etrumadenant (ETRUMA) | Phase 2 | Lung Cancer | - | - |
Platinum-Based Doublet | Phase 2 | Advanced Non-Small Cell Lung Cancer | - | - |
AB680 | Phase 2 | Metastatic Colorectal Cancer | - | - |
Etrumadenant | Phase 2 | Prostatic Neoplasms, Castration-Resistant | - | - |
Etrumadenant (AB928) | Phase 2 | Rectal Cancer | - | - |
Metastatic Colorectal Cancer
1 drug in this indication
Advanced Upper Gastrointestinal Tract Adenocarcinoma
1 drug in this indication
clear cell renal cell carcinoma (ccRCC)
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Arcus Biosciences, Inc.'s drug pipeline?→
CatalystAlert tracks 13 drug candidates in Arcus Biosciences, Inc.'s (RCUS) pipeline across Phase 3, Phase 2. Its lead program is Zimberelimab (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Arcus Biosciences, Inc.'s next FDA catalyst?→
Arcus Biosciences, Inc.'s (RCUS) next tracked catalyst is a Phase 2 readout expected October 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track RCUS biotech catalysts?→
Add RCUS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Arcus Biosciences, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.